Ho latela lintlha tse ho Tataiso ea Tlhahlobo le Phekolo ea Mofets'e oa Popelo (2021) e fanoeng ke Komiti ea Gynecological Oncology ea Mokhatlo oa China oa Anti-Cancer, ho na le linyeoe tse ka bang 604,000 tsa mofetše oa popelo le mafu a 341,000 selemo se seng le se seng, tseo ka bobeli li leng teng. boemo ba bone ho sekhahla le lefu la lihlahala tsa mafu a basali.
Lipalopalo tse amehang li boetse li bonts'a hore liketsahalo tsa mofetše oa popelo o tsoetseng pele sebakeng sa heno o etsa hoo e ka bang 44.9% ea mefuta eohle ea mofets'e oa popelo, 'me boholo ba ona a khutla nakong ea lilemo tse peli ho isa ho tse tharo kamora kalafo. Haholo-holo, sekhahla sa ho phela sa lilemo tse hlano sethaleng sa IIIA-IVA sa mofetše oa popelo e tsoetseng pele sebakeng sa heno se ka tlase ho 60%, moo chemoradiotherapy ea nako e tšoanang e nkuoang e le kalafo e tloaelehileng bakeng sa bakuli ba joalo.
Li-immune checkpoint inhibitors tse kopantsoeng le radiotherapy bakeng sa lihlahala tse tiileng li pakiloe hore li lelefatsa ho phela ha mokuli, empa ha ho li-inhibitors tsa ho itšireletsa mafung bakeng sa mofetše oa popelo o tsoetseng pele oa lehae tse amohetsoeng lefatšeng ka bophara. Ho qaleha ha mohato oa III oa teko ea meriana ea Cadonilimab e kopantsoeng le chemoradiotherapy bakeng sa phekolo ea mofetše oa popelo e tsoetseng pele sebakeng sa heno ho lebeletsoe ho fumana melemo e phahameng ea bongaka, ho ntlafatsa bophelo ba bakuli ba nang le mofetše oa popelo e tsoetseng pele sebakeng sa heno, le ho ba khetho e molemo ka ho fetisisa ea phekolo bakeng sa bakuli. boholo ba bakuli ba mofetše oa popelo nakong e tlang e haufi.Ka nako e ts'oanang, ho qalisoa ha teko ena ea kliniki ho tla ntlafatsa ho ea pele lipontšo tsa sebopeho sa Cadonilimab tšimong ea mofetše oa popelo.
Ho ipapisitsoe le litlamorao tse ntle tsa Cadonilimab tse fumanoeng tekong ea bongaka ea mofets'e oa popelo o iphetang / o sa foleng, CDE e amohetse ts'ebeliso e ncha ea moriana oa Cadonilimab bakeng sa kalafo ea mofets'e oa popelo o iphetang ka Loetse 2021 mme ea fana ka tlhahlobo e tlang pele. Ka hona, Cadonilimab e lebelletsoe ho ba lesole la pele la lefats'e la PD-1 la bi-specific le amohetsoeng bakeng sa ho qala 'maraka.
Ho feta moo, teko ea lefats'e ea lefats'e ea III ea Cadonilimab mmoho le chemotherapy e thehiloeng ho platinum e kopantsoeng le/ntle le bevacizumab kalafong ea pele ea mofets'e oa popelo o pheellang, o iphetang kapa o sa foleng o ile oa qalisoa ka Mots'eanong 2021. Ena ke teko ea pele ea sehlopha sa III ea tlhahlobo ea bongaka. Mola oa pele oa bi-specific antibody immunotherapy bakeng sa mofetše oa popelo naheng ea China.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- The initiation of the phase III clinical trial of Cadonilimab combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer is expected to achieve higher clinical benefits, further improving the survival of patients with locally advanced cervical cancer, and becoming a better targeted treatment option for the majority of cervical cancer patients in the near future.
- Ho latela lintlha tse ho Tataiso ea Tlhahlobo le Phekolo ea Mofets'e oa Popelo (2021) e fanoeng ke Komiti ea Gynecological Oncology ea Mokhatlo oa China oa Anti-Cancer, ho na le linyeoe tse ka bang 604,000 tsa mofetše oa popelo le mafu a 341,000 selemo se seng le se seng, tseo ka bobeli li leng teng. boemo ba bone ho sekhahla le lefu la lihlahala tsa mafu a basali.
- Based on the positive effects of Cadonilimab obtained in the clinical trial of recurrent/ metastatic cervical cancer, CDE accepted the new drug application of Cadonilimab for the treatment of recurrent/metastatic cervical cancer in September 2021 and granted priority review designation.